Epigenetic Modifiers

Introduction to Epigenetics

Epigenetics refers to modifications in gene activity that occur without altering the underlying DNA sequence. Rather than changing the genetic code, these processes regulate whether genes are switched on or off through mechanisms such as chromatin remodeling. This often involves chemical changes to histone proteins or the attachment of methyl or alkyl groups to DNA bases.

Alterations like histone acetylation or methylation can significantly influence chromatin structure, thereby affecting the likelihood of transcription. In a similar way, excessive DNA methylation within a gene’s promoter region can block transcription and prevent gene expression. Because of this, enzymes that control these modifications—such as histone deacetylases and DNA methyltransferases—are being investigated as therapeutic targets, particularly for their potential in treating various forms of cancer.

DNA Methyltransferase (DNMTs)

DNA methyltransferases (DNMTs) primarily catalyze the addition of methyl groups to CpG sites within DNA. In mammals, three enzymatically active DNMTs have been identified: DNMT1, DNMT3A, and DNMT3B. Methylation at promoter regions generally silences gene expression by blocking the ability of transcription factors to bind to DNA. Beyond this, methylated DNA can be recognized by methyl-CpG–binding domain proteins, which in turn recruit histone-modifying enzymes. These enzymes compact chromatin, providing an additional route for gene repression.

In certain cancers, such mechanisms contribute to reduced activity of tumor suppressor genes, promoting uncontrolled cellular proliferation. To counteract this, several agents that inhibit DNMT activity have been developed, including RG-108, mithramycin, and azacytidine.

Histone Methyltransferase Inhibitors

Histone methyltransferases (HMTs) catalyze the addition of methyl groups to lysine and arginine residues on histone proteins, most notably histones H3 and H4. This methylation alters the histone’s chemical properties, reducing its positive charge and slightly loosening its interaction with DNA. As a result, the DNA becomes more accessible, which can promote transcriptional activity. In this way, HMTs may enhance gene expression by facilitating transcription of DNA sequences associated with less compact chromatin.

However, histone methylation is context-dependent and can also repress transcription. Depending on the specific histone residue involved, methylation may obstruct transcription factor binding sites or encourage chromatin condensation, thereby silencing genes. In certain cancers, aberrant activity of methyltransferases such as EZH2 and DOT1L contributes to the repression of tumor suppressor genes. Targeting these enzymes with inhibitors—including EPZ5676, EPZ005687, and GSK126—has demonstrated anticancer efficacy in multiple in vitro and in vivo studies.

Histone Deacetylases (HDACs)

Histone deacetylases (HDACs) function by removing acetyl groups from N-acetyl lysine residues on histone proteins. This deacetylation increases the positive charge on histones, strengthening their interaction with the negatively charged DNA backbone. The result is a more compact chromatin structure, which reduces the likelihood of transcription. Through this mechanism, HDACs can suppress the expression of genes involved in apoptosis and tumor suppression.

HDACs are categorized into four major classes according to their cellular distribution and biological roles. Class I HDACs (isoforms 1, 2, 3, and 8) are predominantly nuclear, whereas Class II HDACs (isoforms 4, 5, 6, 7, 9, and 10) shuttle between the nucleus and cytoplasm. Inhibition of HDAC activity has shown therapeutic potential, particularly in oncology, where HDAC inhibitors enhance the effects of other chemotherapeutic agents. This strategy has been especially effective in treating leukemias and lymphomas. Examples of HDAC inhibitors include vorinostat, trichostatin A, scriptaid, and phenylbutyrate.

Aurora Kina

Aurora kinases comprise a family of serine/threonine kinases that play essential roles in regulating mitosis. Three members—Aurora A, Aurora B, and Aurora C—carry out distinct but complementary functions in chromatid segregation and other aspects of cell division. Overexpression of these kinases has been observed in numerous cancers, highlighting their potential as therapeutic targets.

Inhibition of Aurora kinases triggers apoptosis through specific mechanisms unique to each isoform. Blocking Aurora A disrupts mitotic spindle formation, while inhibition of Aurora B interferes with proper chromosome alignment. The role of Aurora C is less well defined, as it is normally active in meiotic cells; however, emerging evidence suggests it also exhibits oncogenic potential. To date, most drug development efforts have focused on small-molecule inhibitors directed against Aurora A and Aurora B.

Aladdin: https://www.aladdinsci.com/